Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Brian Edward Miller Sells 8,900 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Brian Edward Miller sold 8,900 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $485.07, for a total transaction of $4,317,123.00. Following the sale, the executive vice president now directly owns 5,758 shares of the company’s stock, valued at approximately $2,793,033.06. The trade was a 60.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $497.30 on Thursday. The firm’s 50-day moving average is $569.42 and its 200-day moving average is $531.60. Intuitive Surgical, Inc. has a 1 year low of $364.17 and a 1 year high of $616.00. The company has a market cap of $177.13 billion, a P/E ratio of 77.58, a PEG ratio of 5.85 and a beta of 1.43.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Bennett Selby Investments LP increased its holdings in shares of Intuitive Surgical by 3.9% in the 4th quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 17 shares during the period. Onefund LLC increased its holdings in shares of Intuitive Surgical by 1.9% in the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider’s stock worth $494,000 after acquiring an additional 18 shares during the period. AlphaCore Capital LLC increased its holdings in shares of Intuitive Surgical by 4.2% in the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider’s stock worth $235,000 after acquiring an additional 18 shares during the period. LVW Advisors LLC increased its holdings in shares of Intuitive Surgical by 1.3% in the 4th quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider’s stock worth $756,000 after acquiring an additional 19 shares during the period. Finally, Wesbanco Bank Inc. increased its holdings in shares of Intuitive Surgical by 1.6% in the 4th quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider’s stock worth $635,000 after acquiring an additional 19 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ISRG. JPMorgan Chase & Co. raised their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a report on Friday, January 24th. UBS Group raised their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. Bernstein Bank increased their price objective on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Finally, Jefferies Financial Group increased their price objective on shares of Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and an average target price of $613.10.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.